Catherine Roche
Overview
Explore the profile of Catherine Roche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klos C, Roynard P, Berthon C, Soenen V, Marceau A, Fournier E, et al.
Ann Hematol
. 2024 Aug;
103(11):4793-4795.
PMID: 39207558
No abstract available.
2.
Graillon T, Romanet P, Camilla C, Gelin C, Appay R, Roche C, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2835-2845.
PMID: 38630553
Purpose: Multiple endocrine neoplasia type 1 (MEN1) is thought to increase the risk of meningioma and ependymoma. Thus, we aimed to describe the frequency, incidence, and specific clinical and histological...
3.
Mondielli G, Mougel G, Darriet F, Roche C, Querdray A, Lisbonis C, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139608
Recurrent or high-grade meningiomas are an unmet medical need. Recently, we demonstrated that targeting mTOR by everolimus was relevant both in vitro and in humans. However, everolimus induces an AKT...
4.
Romanet P, Galluso J, Kamenicky P, Hage M, Theodoropoulou M, Roche C, et al.
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34299200
Forty percent of somatotroph tumors harbor recurrent activating mutations, historically called the oncogene. In -negative somatotroph tumors, expression itself is highly variable; those with overexpression most resemble phenotypically those carrying...
5.
Gerard C, Lagarde M, Poizat F, Oziel-Taieb S, Garcia V, Roche C, et al.
Endocr Relat Cancer
. 2020 Oct;
28(1):39-51.
PMID: 33112824
Although there is evidence of a significant rise of neuroendocrine neoplasms (NENs) incidence, current treatments are largely insufficient due to somewhat poor knowledge of these tumours. Despite showing differentiated features,...
6.
Graillon T, Roche C, Basset N, Mougel G, Meyer M, Farah K, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdaa068.
PMID: 32642718
No abstract available.
7.
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, et al.
Clin Cancer Res
. 2020 Jan;
26(3):552-557.
PMID: 31969329
Purpose: Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas....
8.
Gbeto C, Quaranta S, Mari R, Fanciullino R, Roche C, Nahon S, et al.
Pharmacogenomics
. 2019 Sep;
20(13):931-938.
PMID: 31486738
Dihydropryimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with severe or lethal toxicities with oral capecitabine. Usually, patients with history of 5-FU-based therapy with no signs for life-threatening toxicities...
9.
Romanet P, Philibert P, Fina F, Cuny T, Roche C, Ouafik L, et al.
J Pediatr
. 2018 Nov;
205:281-285.e4.
PMID: 30442414
The GNAS postzygotic mosaic activating mutations involved in fibrous dysplasia and McCune-Albright syndrome (MAS) are not detectable in leukocytes by Sanger sequencing. Digital droplet polymerase chain reaction detects GNAS mutations...
10.
Fanciullino R, Farnault L, Donnette M, Imbs D, Roche C, Venton G, et al.
Blood Adv
. 2018 Mar;
2(5):462-469.
PMID: 29490977
Cytarabine (Ara-C) is the backbone of acute myeloid leukemia (AML) chemotherapy. Little is known about possible risk factors predictive for the frequent (ie, up to 16%) life-threatening or lethal toxicities...